Bruker (BRKR)
(Delayed Data from NSDQ)
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Zacks News
MSCI Q2 Earnings and Revenues Beat Estimates, Shares Up
by Zacks Equity Research
MSCI's second-quarter 2021 results benefit from strong growth in recurring subscription revenues and asset-based fees.
Silicon Motion (SIMO) to Post Q2 Earnings: What to Expect?
by Zacks Equity Research
Silicon Motion's (SIMO) second-quarter results are likely to benefit from continued momentum in SSD controller sales, as well as healthy sales of eMMC and UFS controllers.
Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphenol (APH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Amphenol's (APH) second-quarter 2021 results are likely to reflect benefits from a diversified business model and accretive acquisitions.
3 Reasons Why Bruker (BRKR) Is a Great Growth Stock
by Zacks Equity Research
Bruker (BRKR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Bruker (BRKR) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Bruker (BRKR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bruker (BRKR) Updates 2021 Outlook, Issues Medium-Term View
by Zacks Equity Research
Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.
Bruker (BRKR) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Bruker (BRKR) on solid CALID Group growth potential and raised 2021 financial guidance.
Bruker (BRKR) FluoroType Assay Detects New SARS-CoV-2 Variants
by Zacks Equity Research
Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay differentiates and quantifies the SARS-CoV-2 virus in just one PCR test, thereby reducing workload, cost, and time.
Why Is Bruker (BRKR) Up 0.5% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Bruker Corp
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Bruker Corp
Here's Why Momentum Investors Will Love Bruker (BRKR)
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), PerkinElmer (PKI) and Bruker Corporation (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand as well as rising healthcare spending.
3 Reasons Growth Investors Will Love Bruker (BRKR)
by Zacks Equity Research
Bruker (BRKR) could produce exceptional returns because of its solid growth attributes.
Bruker's (BRKR) Research Tools Enable New insight on PACS
by Zacks Equity Research
Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.
Transcat, Inc. (TRNS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Transcat, Inc. (TRNS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Emcore (EMKR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Emcore (EMKR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.
The Zacks Analyst Blog Highlights: Continental Resources, United Parcel Service, Bruker Corp, Molina Healthcare and CDW Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Continental Resources, United Parcel Service, Bruker Corp, Molina Healthcare and CDW Corp
Top 5 Growth Picks Amid Disappointing April Jobs Data
by Nalak Das
We have narrowed down our search to five growth stocks that have popped more than 25 % year to date and still have upside left for 2021. These are: UPS, CLR, MOH, CDW, and BRKR
Large-Cap Stocks Bring Stability to Your Portfolio
by Sejuti Banerjea
Large-caps bring stability to your portfolio because they don't react as aggressively to news and other events.
All You Need to Know About Bruker (BRKR) Rating Upgrade to Buy
by Zacks Equity Research
Bruker (BRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.
Bruker Corporation (BRKR) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
Bruker's (BRKR) revenue improvement in the first quarter is likely to have been boosted by robust performance by all three of its BSI groups.
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.